Eloralintide is not a GLP-1 drug. It is a selective amylin receptor agonist — a different hormone, a different receptor, a different pathway. And in its 48-week phase 2 trial it produced 20% mean weight loss, which is tirzepatide territory. That result is the most interesting thing in the obesity pipeline, because it says the GLP-1 receptor is not the only route to this magnitude of effect.
Why it keeps getting called a GLP-1, and why that is wrong
Eloralintide appears constantly in lists of "next-generation GLP-1 drugs". It does not act on the GLP-1 receptor at all.
Amylin is a separate hormone, released by the pancreas alongside insulin whenever you eat. It slows gastric emptying and signals satiety through its own receptors in the brainstem. The pathway overlaps with GLP-1 in what it achieves and not in how it gets there.
The distinction has consequences. An amylin drug can be combined with a GLP-1 rather than competing with it — which is exactly what is being tested, with eloralintide studied both alone and alongside tirzepatide. Two drugs that hit the same receptor cannot be stacked; two that hit different ones can.
Where it stands
| Status | Investigational — phase 3, recruiting |
| Developer | Eli Lilly |
| Code name | LY3841136 |
| Class | Selective amylin receptor agonist — not a GLP-1 |
| Administration | Once-weekly subcutaneous injection |
| Registered studies | 16 |
| Published result | 20% mean weight loss at 48 weeks (phase 2) |
The phase 2 results
Published in the Lancet in December 2025: 263 adults with obesity, or overweight plus a weight-related condition and without type 2 diabetes, randomised across six eloralintide regimens or placebo for 48 weeks. Mean baseline weight was 109.1 kg and mean BMI 39.1.
| Dose | Mean weight change at 48 weeks |
|---|---|
| Placebo | −0.4% |
| 1 mg | −9% |
| 3 mg | −12% |
| 3 → 9 mg | −16% |
| 6 mg | −18% |
| 6 → 9 mg | −20% |
| 9 mg | −20% |
For scale: semaglutide reaches about 14.9% and tirzepatide about 20.9% in their own obesity trials. Eloralintide's 20% at 48 weeks sits between them — from a phase 2 trial, over a shorter period, with no GLP-1 activity whatsoever.
The usual caveats hold. 263 people is a phase 2, results often soften at scale, and 48 weeks is shorter than the 68 to 72 weeks the approved comparisons ran.
The finding in the safety data that nobody is writing about
Nausea by treatment arm looks wrong at first glance:
| Arm | Weight loss | Nausea | Fatigue |
|---|---|---|---|
| Placebo | −0.4% | 14% | 12% |
| 1 mg | −9% | 11% | 0% |
| 3 mg | −12% | 13% | 13% |
| 3 → 9 mg | −16% | 25% | 21% |
| 6 mg | −18% | 64% | 29% |
| 6 → 9 mg | −20% | 54% | 46% |
| 9 mg | −20% | 33% | 43% |
Read the 6 mg row against the 9 mg row. The lower dose produced less weight loss and roughly twice the nausea. That is not how dose-response is supposed to work.
The explanation is in the escalation. This trial tested fixed doses alongside stepped ones, and the pattern that emerges is that the starting dose predicts nausea better than the final dose does. The arm climbing from 3 mg reached 16% weight loss with 25% nausea. The arm sitting at 6 mg reached 18% with 64%. Two arms ended at 9 mg with very different nausea depending on where they began.
If that holds, it is a practically important finding: a slower start buys most of the result at a fraction of the discomfort. It is also a reminder that fixed-dose arms in early trials can make a drug look harsher than it needs to be. Fatigue, notably, tracks the final dose rather than the starting one — 43% at 9 mg — so the two side effects are behaving differently.
Why an amylin drug matters strategically
Every approved weight-loss drug works through the GLP-1 receptor. Tirzepatide adds GIP, retatrutide adds glucagon, but GLP-1 is in all of them. That makes the whole category dependent on one pathway, with one shared tolerability profile and one shared set of non-responders.
An amylin drug that reaches 20% on its own breaks that dependency. Three consequences follow:
- Combinations become the obvious next step. Eloralintide is being studied with tirzepatide, and CagriSema already pairs an amylin analogue with semaglutide. Different receptors add rather than compete.
- People who cannot tolerate GLP-1s get an option that is not simply a lower dose of the same thing.
- The side effect profile may differ. The fatigue figures here, up to 46%, are higher than the GLP-1 drugs report, while the nausea in the well-escalated arms is lower. Different pathway, different trade.
Other amylin molecules are in development — cagrilintide at Novo Nordisk, petrelintide at Zealand — and the whole set is in the GLP-1 pipeline tracker.
What is not known
- Phase 3 results. Sixteen studies are registered and the programme reaches phase 3, but no phase 3 efficacy data has been published.
- The combination results. Eloralintide with tirzepatide is in trials; nothing has reported.
- Long-term safety. Forty-eight weeks in 263 people cannot show what is rare.
- Whether 20% survives scale. Phase 2 figures routinely come down in phase 3.
Can you get it?
No. Eloralintide is not approved by any regulator and cannot be prescribed. It is in phase 3 and recruiting, so trial enrolment is the only legitimate route, and that is a conversation for a clinician.
Anything sold online under the name carries the problems documented for unapproved peptides generally — unverified identity, unverified strength, no accountability. The evidence on what those products actually contain is in the retatrutide overview, where three vials of another unapproved molecule were analysed and held between half and nearly double their labelled dose.
The options available today are ranked in the best GLP-1 for weight loss.
Everything on eloralintide
- What is eloralintide? — the short version, starting with the fact that it is not a GLP-1.
- Eloralintide weight loss — all six trial arms, and why the final dose sets the result.
- Eloralintide side effects — nausea follows the start, fatigue the finish.
- Eloralintide vs Zepbound — Lilly is testing them together.
- Eloralintide vs Wegovy — bigger number, different hormone.
- Eloralintide vs Ozempic — never studied in the same population.
Scientific References
3 sources- 1
Billings LK, Hsia S, Bays H, et al.
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
The Lancet · 406(10520) · 2025PMID: 41207310
- 2
U.S. National Library of Medicine
ClinicalTrials.gov — eloralintide (LY3841136) registered studies: 16 total, maximum phase 3, recruiting, lead sponsor Eli Lilly; read 13 August 2026
ClinicalTrials.gov · 2026
- 3
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
New England Journal of Medicine · 387(3) · 2022PMID: 35658024
NEJM
References open in a new tab. Content is reviewed against peer-reviewed literature as part of our editorial policy.
About the author
Editor, Modern Weight Science
Claudiu Gheorghe is the editor of Modern Weight Science. He is not a physician. His role is to synthesize peer-reviewed studies, clinical-trial data, and FDA prescribing information into clear, plain-language explanations, and to make sure every factual claim on the site traces back to a cited source. Any decision about starting, changing, or stopping a medication belongs with a licensed clinician who knows your history.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
What is eloralintide?
An investigational once-weekly injection from Eli Lilly, known in trials as LY3841136. It is a selective amylin receptor agonist — amylin is a hormone released with insulin that signals satiety — and it does not act on the GLP-1 receptor at all, despite frequently being listed among next-generation GLP-1 drugs. It is in phase 3 and is not approved.
Is eloralintide a GLP-1 drug?
No. It targets the amylin receptor, a different hormone pathway entirely. The confusion is understandable because it is developed for the same purpose and produces a similar effect, but the mechanism is separate — which is precisely why it can be combined with a GLP-1 rather than competing with one. It is being studied both alone and alongside tirzepatide.
How much weight loss does eloralintide cause?
In its 48-week phase 2 trial, mean weight loss was 20% on the 9 mg dose against 0.4% on placebo, with 18% at 6 mg, 12% at 3 mg and 9% at 1 mg. For comparison, semaglutide reaches about 14.9% and tirzepatide about 20.9% in their own trials. This came from 263 people over 48 weeks, so it is a phase 2 result and may soften at scale.
What are eloralintide's side effects?
Nausea and fatigue, and the pattern is unusual. Nausea ran 64% on the fixed 6 mg arm but only 33% at 9 mg and 25% on the arm that escalated from 3 mg to 9 mg — so the starting dose predicted nausea better than the final dose. Fatigue behaved differently, tracking the top dose and reaching 43 to 46%. Fatigue at those rates is higher than the GLP-1 drugs typically report.
Can eloralintide be combined with Zepbound?
That is being tested. Because eloralintide works through the amylin receptor rather than GLP-1, it can be added to a GLP-1 drug rather than competing for the same target, and trials of eloralintide with tirzepatide are registered. No results have been published. The same logic underlies CagriSema, which pairs an amylin analogue with semaglutide.
When will eloralintide be available?
There is no approval date. The programme has reached phase 3 with sixteen registered studies, and no phase 3 efficacy results have been published. A manufacturer files after its pivotal trials report and a regulator then takes its own time.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.